Evidence map›Paper›PMID 36113507›Full record

ArticleThe lancet. Diabetes & endocrinology2022

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.

Gabriel A Gregory, Thomas I G Robinson, Sarah E Linklater, Fei Wang, Stephen Colagiuri, Carine de Beaufort, Kim C Donaghue, International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest Group, Dianna J Magliano, Jayanthi Maniam and 3 more

Erratum issued 2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 629 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
629citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07503028 early_phase1enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

TypeinterventionalSponsorCelregen TherapeuticsRan2025 to 2028Enrolled10ConditionsT1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes MellitusArmsCRG002
NCT07583238 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Assessing the Impact of Intraoperative Diathermy on Accuracy and Functioning of Glucose Monitoring Systems

Typeobservational_patient_registrySponsorUniversity of NottinghamRan2026 to 2027Enrolled126ConditionsType 1 Diabetes Mellitis
3 · Its place in the literature

Who cites it

629 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Observational
  15. Article
  16. Article
  17. Economic Burden of Type 1 Diabetes in France.Diabetes, obesity & metabolism · 2026
    Article
  18. Article
  19. Article
  20. Article

569 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Gabriel A GregoryLife for a Child Program, Diabetes NSW, Glebe, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.
Thomas I G RobinsonJDRF Australia, St Leonards, NSW, Australia.
Sarah E LinklaterJDRF Canada, North York, ON, Canada.
Fei WangJDRF Australia, St Leonards, NSW, Australia.
Stephen ColagiuriCharles Perkins Centre and Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
Carine de BeaufortDECCP, Pediatric Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg; Department of Science, Technology and Medicine, University of Luxembourg, Luxembourg.
Kim C DonaghueSydney Medical School, University of Sydney, Camperdown, NSW, Australia; Children's Hospital at Westmead, Westmead, NSW, Australia.
International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest Group
Dianna J MaglianoBaker Heart and Diabetes Institute, Melbourne, VIC, Australia; Monash University, School of Public Health and Preventive Medicine, Melbourne, VIC, Australia.
Jayanthi ManiamLife for a Child Program, Diabetes NSW, Glebe, NSW, Australia.
Trevor J OrchardDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Priyanka RaiJDRF Australia, St Leonards, NSW, Australia.
Graham D OgleLife for a Child Program, Diabetes NSW, Glebe, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia. Electronic address: grahamo@diabetesnsw.com.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on available data to estimate these values for 201 countries for the year 2021 and estimate the projected prevalent cases in 2040.

methodsWe fitted a discrete-time illness-death model (Markov model) to data on type 1 diabetes incidence and type 1 diabetes-associated mortality to produce type 1 diabetes prevalence, incidence, associated mortality and life expectancy in all countries. Type 1 diabetes incidence and mortality data were available from 97 and 37 countries respectively. Diagnosis rates were estimated using data from an expert survey. Mortality was modelled using random-forest regression of published type 1 diabetes mortality data, and life expectancy was calculated accordingly using life tables. Estimates were validated against observed prevalence data for 15 countries. We also estimated missing prevalence (the number of additional people who would be alive with type 1 diabetes if their mortality matched general population rates).

findingsIn 2021, there were about 8·4 (95% uncertainty interval 8·1-8·8) million individuals worldwide with type 1 diabetes: of these 1·5 million (18%) were younger than 20 years, 5·4 million (64%) were aged 20-59 years, and 1·6 million (19%) were aged 60 years or older. In that year there were 0·5 million new cases diagnosed (median age of onset 39 years), about 35 000 non-diagnosed individuals died within 12 months of symptomatic onset. One fifth (1·8 million) of individuals with type 1 diabetes were in low-income and lower-middle-income countries. Remaining life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021 ranged from a mean of 13 years in low-income countries to 65 years in high-income countries. Missing prevalent cases in 2021 were estimated at 3·7 million. In 2040, we predict an increase in prevalent cases to 13·5-17·4 million (60-107% higher than in 2021) with the largest relative increase versus 2021 in low-income and lower-middle-income countries.

interpretationThe burden of type 1 diabetes in 2021 is vast and is expected to increase rapidly, especially in resource-limited countries. Most incident and prevalent cases are adults. The substantial missing prevalence highlights the premature mortality of type 1 diabetes and an opportunity to save and extend lives of people with type 1 diabetes. Our new model, which will be made publicly available as the Type 1 Diabetes Index model, will be an important tool to support health delivery, advocacy, and funding decisions for type 1 diabetes.

fundingJDRF International.

Indexed as

Diabetes Mellitus, Type 1AdultChildGlobal HealthHumansIncidenceLife ExpectancyPrevalence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.